TrialHuman vaccines & immunotherapeutics2022

Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study.

Renfeng Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.